A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy

医学 帕利骨化醇 吉西他滨 伊立替康 胰腺癌 内科学 肿瘤科 临床终点 不利影响 粘膜炎 胃肠病学 化疗 癌症 泌尿科 继发性甲状旁腺功能亢进 结直肠癌 随机对照试验 甲状旁腺激素 钙
作者
Patrick Grierson,Rama Suresh,Benjamin Tan,Katrina Pedersen,Manik Amin,Haeseong Park,Nikolaos A. Trikalinos,Jingxia Liu,Nicholas Boice,Amberly Brown,Sapana Bansod,Andrea Wang‐Gillam,Kian‐Huat Lim
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:29 (23): 4733-4739
标识
DOI:10.1158/1078-0432.ccr-23-1405
摘要

Abstract Purpose: Vitamin D analogues remodel the desmoplastic stroma, and improve vascularity and efficacy of chemotherapy in preclinical pancreas cancer models. Patients and Methods: We conducted a pilot study to evaluate the safety and preliminary efficacy of the vitamin D analogue paricalcitol in combination with nanoliposomal irinotecan (Nal-iri) plus 5-fluorouracil/leucovorin (5-FU/LV) in patients with advanced pancreatic cancer who had progressed on gemcitabine-based therapy. Two dose levels (DL) of paricalcitol were tested: fixed dose weekly (75 mcg, DL1) and weight-based weekly (7 mcg/kg, /DL2). The primary endpoint was safety, and secondary endpoints included overall response rate, progression-free survival (PFS), and overall survival (OS). Correlative objectives aimed to identify molecular predictors of response and alterations in the tumor stroma. Results: Twenty patients (10 each in DL1 and DL2) enrolled between March 2019 and May 2021. No grade 3/4 adverse events related to paricalcitol were observed. The most common toxicities were nausea, diarrhea and fatigue, which were similar in both cohorts. Three patients discontinued study after one cycle and were not radiographically evaluable. Of the remaining 17 evaluable patients, 2 had partial response and 12 had stable disease. The median PFS for response-evaluable patients in DL1 was 4.14 months, for DL2 was 4.83 months. Intent-to-treat median OS was 6.15 and 6.66 months for DL1 and DL2, respectively. Correlative studies showed increased tumor vascularity in posttreatment samples in patients receiving the higher dose of paricalcitol (DL2). Conclusions: Paricalcitol at 7 mcg/kg/week in combination with Nal-iri/ 5-FU/LV is safely tolerated, may increase tumor vascularity and warrants further investigation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gao完成签到,获得积分10
刚刚
脑洞疼的应助被succo采纳,获得10
1秒前
syvshc的应助被Yonnn采纳,获得10
1秒前
烟花的应助被默默灵煌采纳,获得10
1秒前
1秒前
ku发布了新的文献求助20
2秒前
完美世界的应助被三分之二采纳,获得10
2秒前
Harry发布了新的文献求助20
2秒前
自然的以亦完成签到,获得积分10
2秒前
Zyj完成签到,获得积分10
3秒前
yjswjf完成签到,获得积分10
4秒前
一笑没的应助被苏苏采纳,获得10
4秒前
卷卷完成签到,获得积分10
5秒前
7秒前
7秒前
1900发布了新的文献求助10
7秒前
mm发布了新的文献求助10
7秒前
灝男发布了新的文献求助10
7秒前
9秒前
9秒前
Ann发布了新的文献求助10
9秒前
10秒前
灝男发布了新的文献求助10
11秒前
Dong完成签到 ,获得积分10
11秒前
11秒前
11秒前
molihuakai的应助被三分之二采纳,获得10
12秒前
12秒前
Asana完成签到 ,获得积分10
12秒前
王三岁完成签到,获得积分10
12秒前
QinMengYao完成签到 ,获得积分10
12秒前
13秒前
灝男发布了新的文献求助30
13秒前
melisa发布了新的文献求助10
14秒前
苹果丑发布了新的文献求助30
14秒前
朝槿完成签到,获得积分10
14秒前
直率的翎完成签到,获得积分10
15秒前
15秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177802
求助须知:如何正确求助?哪些是违规求助? 9568632
关于积分的说明 21799933
捐赠科研通 7772424
什么是DOI,文献DOI怎么找? 3432505
关于科研通互助平台的介绍 2556698
邀请新用户注册赠送积分活动 2478055